Facing entrenched structural issues, the eurozone's days of robust growth are likely over, but there are some reasons for hope, says Morningstar's Bob Johnson.
OzForex's low-cost, online business model could prove to be a meaningful market disruptor, and the shares look like a bargain today.
Shifts in management lead to a downgrade for Ivy High Income and a Neutral rating for Ivy Asset Strategy.
High customer switching costs give specialized cellulose producer Rayonier a competitive advantage, and the shares look cheap, too.
Although a drawdown in the short term is a real possibility, investors should still see a 4.5% to 6% real return over the long run, says Morningstar's Matt Coffina.
Kinder's reorganization brings upside potential, but even after the change, its payout coverage is too thin for conservative income investors, says Morningstar DividendInvestor editor Josh Peters.
The month-to-month numbers look frightful, but year-over-year growth is in line with recent trends, says Morningstar's Bob Johnson.
Retired investors can tilt their portfolios to the safer side with these funds, says Morningstar's Christine Benz.
MainStay ICAP International recently experienced some management changes, but it's still a solid choice for overseas exposure at a reasonable price.
Passive funds continued to attract investor dollars in July, but active management is still preferred for overseas exposure.
Plus, the difference a moat makes in retail, the long view on Cisco, and more.
Investors concerned with Express Scripts' integration of Medco are overlooking the firm's long-term potential to benefit from an increased focus on health-care cost-cutting, says Morningstar StockInvestor editor Matt Coffina.
©2014 Morningstar Advisor. All right reserved.